Research programme: inflammation therapeutics - AtheroGenicsAlternative Names: MEKK inhibitors - AtheroGenics
Latest Information Update: 11 May 2009
At a glance
- Originator National Jewish Medical and Research Center
- Developer AtheroGenics
- Mechanism of Action MAP kinase kinase kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Inflammation